Literature DB >> 22972655

Making a case for the socioeconomic determinacy of survival in osteosarcoma.

Saminathan S Nathan1, John H Healey.   

Abstract

BACKGROUND: The literature on osteosarcoma survival generally focuses on tumor and treatment variables, although it is unclear whether and how ethnic and socioeconomic factors might influence survival. QUESTIONS/PURPOSES: We therefore investigated the relative contribution of socioeconomic influences together with more traditional tumor-specific factors on osteosarcoma survival.
METHODS: We performed survival analyses on two national databases in two countries. Using multivariable analyses, we compared these with corresponding institution-specific survival to determine if socioeconomic factors might impact osteosarcoma survival.
RESULTS: East Asian descent, state-specific treatment, female sex, treatment in the 1990s, low-grade disease, intracompartmental disease, small size, wide resections as opposed to forequarter or hindquarter amputations, and single primaries were good prognostic factors. Survival was better in the more affluent states. Males were affected at an older age than females. Blacks tended to have larger tumors, although their overall survival was similar to whites. East Asians were more likely to be treated in the 1990s with wide resections for smaller tumors and were located around states associated with good treatment. East Asians in Singapore and the United States had the same survival. Survival in East Asians in Singapore was similar to that of other races. The provision of health care for osteosarcoma varies greatly across the United States but is uniform in the socialized medical system in Singapore. Hence, the observed differences in the United States were likely the result of socioeconomic factors.
CONCLUSIONS: Our analysis suggests ethnic and economic bias may influence survival in osteosarcoma and should receive greater attention in the collective literature on survival analyses. LEVEL OF EVIDENCE: Level II, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Year:  2013        PMID: 22972655      PMCID: PMC3563779          DOI: 10.1007/s11999-012-2575-1

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  17 in total

1.  Recent advances in the chemotherapy of metastatic osteogenic sarcoma.

Authors:  N Jaffe
Journal:  Cancer       Date:  1972-12       Impact factor: 6.860

2.  Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases.

Authors:  R C Marcove; V Miké; J V Hajek; A G Levin; R V Hutter
Journal:  J Bone Joint Surg Am       Date:  1970-04       Impact factor: 5.284

3.  Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol.

Authors:  G Bacci; A Briccoli; S Ferrari; A Longhi; M Mercuri; R Capanna; D Donati; S Lari; C Forni; M DePaolis
Journal:  Eur J Cancer       Date:  2001-11       Impact factor: 9.162

4.  High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.

Authors:  G Bacci; S Ferrari; A Longhi; P Picci; M Mercuri; T A Alvegard; G Saeter; D Donati; M Manfrini; S Lari; A Briccoli; C Forni
Journal:  J Chemother       Date:  2002-04       Impact factor: 1.714

5.  Glucose-6-phosphate dehydrogenase deficiency in Chinese.

Authors:  H C Lai; M P Lai; K S Leung
Journal:  J Clin Pathol       Date:  1968-01       Impact factor: 3.411

6.  Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement.

Authors:  A G Huvos; G Rosen; R C Marcove
Journal:  Arch Pathol Lab Med       Date:  1977-01       Impact factor: 5.534

7.  NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide.

Authors:  H K Parekh; N E Sladek
Journal:  Biochem Pharmacol       Date:  1993-09-14       Impact factor: 5.858

8.  Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.

Authors:  Mark M Zalupski; Cathryn Rankin; James R Ryan; David R Lucas; Jeffrey Muler; Keith S Lanier; George Thomas Budd; J Sybil Biermann; Frederick J Meyers; Karen Antman
Journal:  Cancer       Date:  2004-02-15       Impact factor: 6.860

9.  Osteogenic sarcoma: eight-percent, three-year, disease-free survival with combination chemotherapy (T-7).

Authors:  G Rosen; A Nirenberg; B Caparros; H Juergens; C Kosloff; B M Mehta; R C Marcove; A G Huvos
Journal:  Natl Cancer Inst Monogr       Date:  1981-04

10.  Human liver aldehyde dehydrogenase in Chinese and Asiatic Indians: gene deletion and its possible implications in alcohol metabolism.

Authors:  Y S Teng
Journal:  Biochem Genet       Date:  1981-02       Impact factor: 1.890

View more
  3 in total

1.  Bias in Rating of Rodent Distress during Anesthesia Induction for Anesthesia Compared with Euthanasia.

Authors:  Brittany A Baker; Debra L Hickman
Journal:  J Am Assoc Lab Anim Sci       Date:  2018-03-01       Impact factor: 1.232

2.  Population-Based Analysis of Demographic and Socioeconomic Disparities in Pediatric CNS Cancer Survival in the United States.

Authors:  Robert Fineberg; Shadi Zahedi; Megan Eguchi; Muriel Hart; Myles Cockburn; Adam L Green
Journal:  Sci Rep       Date:  2020-03-12       Impact factor: 4.379

3.  Relationship between red cell distribution width and prognosis of patients with osteosarcoma.

Authors:  Jian Zheng; Xiaopin Yuan; Weichun Guo
Journal:  Biosci Rep       Date:  2019-12-20       Impact factor: 3.840

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.